IN2014DN09297A - - Google Patents

Info

Publication number
IN2014DN09297A
IN2014DN09297A IN9297DEN2014A IN2014DN09297A IN 2014DN09297 A IN2014DN09297 A IN 2014DN09297A IN 9297DEN2014 A IN9297DEN2014 A IN 9297DEN2014A IN 2014DN09297 A IN2014DN09297 A IN 2014DN09297A
Authority
IN
India
Prior art keywords
nanoparticles
methods
octylcyanoacrylate
exendin
obesity
Prior art date
Application number
Other languages
English (en)
Inventor
Sean Matthew Cleveland
Mark Andrew Paulik
Stefan Salomon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IN2014DN09297A publication Critical patent/IN2014DN09297A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN9297DEN2014 2012-05-16 2013-05-16 IN2014DN09297A (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261647633P 2012-05-16 2012-05-16
PCT/IB2013/000964 WO2013171570A1 (en) 2012-05-16 2013-05-16 Polypeptide loaded poca nanoparticles for oral administration

Publications (1)

Publication Number Publication Date
IN2014DN09297A true IN2014DN09297A (cs) 2015-07-10

Family

ID=48577784

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9297DEN2014 IN2014DN09297A (cs) 2012-05-16 2013-05-16

Country Status (10)

Country Link
US (1) US20150342897A1 (cs)
EP (1) EP2849775A1 (cs)
JP (1) JP2015523332A (cs)
KR (1) KR20150010953A (cs)
CN (1) CN104411321A (cs)
AU (1) AU2013261214A1 (cs)
CA (1) CA2873536A1 (cs)
IN (1) IN2014DN09297A (cs)
RU (1) RU2014150850A (cs)
WO (1) WO2013171570A1 (cs)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104799440B (zh) * 2014-01-23 2016-06-08 香港纺织及成衣研发中心有限公司 改善代谢综合症的功能服及其制造方法
CN105342999A (zh) * 2014-08-18 2016-02-24 山东绿叶制药有限公司 艾塞那肽口服纳米粒
CN109675020B (zh) * 2019-01-11 2021-05-04 浙江大学 一种口服glp-1多肽类纳米制剂及其制备方法和应用
US12284984B2 (en) 2020-12-18 2025-04-29 Spectrum Brands, Inc. Grooming tool for animal and methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011457A1 (en) 1990-01-24 1991-08-08 Buckley Douglas I Glp-1 analogs useful for diabetes treatment
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
CA2262647C (en) 1996-08-08 2007-12-04 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
WO1999007404A1 (en) 1997-08-08 1999-02-18 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
AU757748B2 (en) 1997-11-14 2003-03-06 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
ATE383867T1 (de) 1997-11-14 2008-02-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
ES2291017T3 (es) 1998-02-13 2008-02-16 Amylin Pharmaceuticals, Inc. Efectos inotropicos y diureticos de la exendina y glp-1.
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するglp−1のglp−1誘導体及びエキセンジン
JP2004528014A (ja) 2000-12-07 2004-09-16 イーライ・リリー・アンド・カンパニー Glp−1融合タンパク質
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2990417A1 (en) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin insulin fusion protein
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
AU2004273573B2 (en) 2003-09-19 2010-04-22 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
JP5570721B2 (ja) 2005-06-17 2014-08-13 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ナノ粒子の製造方法、システム、及び材料
US20080138418A1 (en) * 2006-12-07 2008-06-12 Tong Shen Enterprise Co., Ltd. Nanoparticles composed of alkyl-cyanoacrylate polymers
EP2207670B1 (en) 2007-10-12 2019-05-22 Liquidia Technologies, Inc. Method for producing particles and patterned films

Also Published As

Publication number Publication date
US20150342897A1 (en) 2015-12-03
AU2013261214A1 (en) 2014-11-20
KR20150010953A (ko) 2015-01-29
RU2014150850A (ru) 2016-07-10
JP2015523332A (ja) 2015-08-13
CA2873536A1 (en) 2013-11-21
WO2013171570A1 (en) 2013-11-21
EP2849775A1 (en) 2015-03-25
CN104411321A (zh) 2015-03-11

Similar Documents

Publication Publication Date Title
IN2014MN02132A (cs)
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
MX2014015258A (es) Variantes del factor 21 de crecimiento de fibroblasto.
TN2014000096A1 (en) Fibroblast growth factor 21 variants
IN2014KN02830A (cs)
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
MX2013008851A (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
IN2012DN06720A (cs)
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
WO2011141685A3 (fr) Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants
AU2016219650A1 (en) Compositions and methods for extended therapy with aminopyridines
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
PH12013500784A1 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
IN2014DN09297A (cs)
TN2015000267A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
IN2014MN02156A (cs)
MX2013013079A (es) Composiciones que comprenden un agente antibacterial y tazobactam.
GB201108343D0 (en) Honey composition
MY197454A (en) Non-enteric pharmaceutical composition comprising crofelemer
UA112981C2 (uk) Варіант людського gdnf